Therapeutic Targeting of Lewisy and Lewisb with a Novel Monoclonal Antibody 692/29

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Noble, Philip ^a   Spendlove, Ian ^a   Harding, Stephen ^a   Parsons, Tina ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; FLUOROURACIL; FOLINIC ACID; LEWIS B ANTIGEN; LEWIS Y ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 692 29; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL KILLING; CELLULAR DISTRIBUTION; COLORECTAL TUMOR; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; GLYCOBIOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DEATH; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; LEWIS BLOOD-GROUP SYSTEM;

EID: 84873668940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054892     Document Type: Article

References (36)

1. Sakamoto J, Watanabe T, Tokumaru T, Takagi H, Nakazato H, et al. (1989) Expression of Lewisa, Lewisb, Lewisx, Lewisy, Sialyl-Lewisa and Sialyl-Lewisx Blood Group Antigens in Human Gastric Carcinoma and in Normal Gastric Tissue. Can Res 49: 745-752.
2. Sakamoto J, Furukawa K, Cordon-Cardo C, Yin BW, Rettig WJ, et al. (1986) Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 46: 1553-1561.
3. Itzkowitz SH (1992) Blood group-related carbohydrate antigen expression in malignant and premalignant colonic neoplasms. J Cell Biochem Suppl 16G: 97-101.
4. Kim YS, Yuan M, Itzkowitz SH, Sun Q, Kaizu T, et al. (1986) Expression of Ley and extended Ley blood group-related antigens in human malignant, premalignant and non malignant colonic tissues. Can Res 46: 5985.
5. Abe K, Hakomori S, Ohshiba S, (1986) Differential expression of difucosyl type 2 chain (LeY) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas. Cancer Res 46: 2639-2644.
6. Hakomori S, (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45: 2405-2414.
7. Brown A, Feizi T, Gooi HC, Embleton MJ, Picard JK, et al. (1983) A monoclonal antibody against human colonic adenoma recognises difucosylated type-2 blood group chains. Biosci Rep 3: 163.
8. Brown A, Ellis IO, Embleton MJ, Baldwin RW, Turner DR, et al. (1984) Immunohistochemical localization of Y hapten and structurally related type-2 blood group antigen on large bowel tumours and normal adult tissues. Int J Cancer 33: 727.
9. Durrant LG, Singhal A, Jacobs E, Price MR, (1993) Development Of 2nd-Generation Monoclonal-Antibodies Recognizing Lewis(Y/B) Antigen By Antiidiotypic Immunization. Hybridoma 12: 647-660.
10. Durrant LG, Robins RA, Baldwin RW, (1989) Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer. JNatl Cancer Inst 81: 688-695.
11. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D, (2000) A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6: 78-81.
12. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, et al. (2000) Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 18: 2282-2292.
13. Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, et al. (2007) A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res 13: 3286-3292.
14. Vandonselaar M, Delbaere LT, Spohr U, Lemieux RU, (1987) Crystallization of the lectin IV of Griffonia simplicifolia and its complexes with the Lewis b and Y human blood group determinants. J Biol Chem 262: 10848-10849.
15. Ramsland P, Farrugia W, Bradford T, Hogarth P, Scott A, (2004) Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J Mol Biol 340: 809-818.
16. Partyka K, Maupin KA, Brand RE, Haab BB (2012) Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics.
17. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, et al. (2005) High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 7: R780-787.
18. Masayuki W, Tomohiro S, Toshihito S, Taiichi N, Takayuki I, et al. (1995) Lewis Y antigen expression in hepatocellular carcinoma. An immunohistochemical study. Cancer 75: 2827-2835.
19. Manimala JC, Roach TA, Li Z, Gildersleeve JC, (2007) High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 17: 17C-23C.
20. Tolcher A, Sugarman S, Gelmon K, Cohen R, Saleh M, et al. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17: 478-484.
21. Kitamura K, Stockert E, Garin-Chesa P, Welt S, Lloyd KO, et al. (1994) Specificity analysis of blood group Lewis-y (Ley) antibodies generated against synthetic and natural Ley determinants. Proc Natl Acad Sci 91: 12957-12961.
22. Brodin T, Cherster AM, Karlsson K-A, Messeter L, Zopf D, et al. (1987) A monoclonal antibody that recognizes both leb and Y (Ley) antigens. Glycoconjugate Journal 4: 339-406.
23. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, et al. (2005) Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 102: 19051-19056.
24. Garrigues J, Garrigues U, Hellstrom I, Hellstrom KE, (1993) Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 142: 607-622.
25. Pryde JG, Walker A, Rossi AG, Hannah S, Haslett C, (2000) Temperature-dependent arrest of neutrophil apoptosis. Failure of Bax insertion into mitochondria at 15 degrees C prevents the release of cytochrome c. J Biol Chem 275: 33574-33584.
26. Loo D, Pryer N, Young P, Liang T, Coberly S, et al. (2007) The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 6: 856-865.
27. Burris HA 3rd, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, et al (2010) Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res 16: 1673-1681.
28. Zhang C, Xu Y, Gu J, Schlossman SF, (1998) A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci U S A 95: 6290-6295.
29. Tan HL, Fong WJ, Lee EH, Yap M, Choo A, (2009) mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 27: 1792-1801.
30. Hernandez AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, et al. (2011) Anti-NeuGcGM3 Antibodies, Actively Elicited by Idiotypic Vaccination in Nonsmall Cell Lung Cancer Patients, Induce Tumor Cell Death by an Oncosis-Like Mechanism. J Immunol.
31. Schreiber GJ, Hellstrom KE, Hellstrom I, (1992) An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res 52: 3262-3266.
32. Watson SA, Morris TM, Crosbee DM, Hardcastle JD, (1993) A hepatic invasive human colorectal xenograft model. Eur J Cancer 29A: 1740-1745.
33. Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, et al. (2005) Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 3: 47.
34. Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG, (2007) The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol 5: 31.
35. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, et al. (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59: 926-933.
36. Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, et al. (2006) Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 55: 973-980.